At a glance
ClinicalIndex Comparison Record- ✓Confirmed diagnosis of DLBCL, FL, or MCL
- ✓Eligible to receive standard of care CAR T cells
- ✓At least 1 prior therapy received
- ✕Active HIV or hepatitis B or C infection
- ✕Active uncontrolled systemic fungal, bacterial or viral infection
- ✕Active treatment for another cancer
- ✕Pregnant or breastfeeding
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
In Brief
A Phase 1 clinical trial evaluating Tazemetostat Pill for Follicular Lymphoma and 3 related conditions. Active but no longer recruiting, targeting 15 participants across 1 site.
Signals
Detailed Summary
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.
Study Details
Timeline
Interventions
Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.